Test drug JAB-21822 for KRAS G12C NSCLC with STK11
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies how well the drug JAB-21822 works in people with advanced or spread lung cancer (NSCLC) that has a specific genetic change: KRAS G12C, plus STK11 and no KEAP1 change. It’s designed to see safety and early signs of effectiveness, especially if you haven’t been treated much yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (NSCLC) confirmed by pathology (a lab test on tissue or cells).
- Your tumor has KRAS G12C mutation found on molecular testing, and you also have STK11 co-mutation.
- Your tumor must be KEAP1 “wild-type” (meaning no KEAP1 mutation), confirmed by testing for the study.
- You have not had treatment for advanced NSCLC yet, or you have had at least one standard treatment.
- Your general functioning score is ECOG 0–1 (you can do most daily activities or are limited but able to do self-care).
- You cannot have certain brain/meninges problems (unless treated brain spots have been stable for at least 28 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
This study tests a new treatment for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The treatment is designed to help the immune system attack cancer cells with this mutation, and the study aims to see if it is safe and effective.
This trial tests a new drug called HS-10370 combined with other anti-cancer treatments for people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if this combination can shrink or control tumors better than other options.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.